Navigation Links
YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
Date:10/1/2010

inistered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with a potential best-in-class side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is a uniquely orally-available agent with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
2. YM BioSciences reports fiscal year end 2010 operational and financial results
3. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
8. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
9. Ambit Biosciences Announces Transition in Company Leadership
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Calithera Biosciences Closes $40 Million in Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015   Intrexon Corporation ... biology, announced today the appointment of Olivier ... Consumer Sector.  Mr. Jarry will lead the expansion ... and applications for consumer markets.  ... of experience in leading global life sciences and ...
(Date:6/2/2015)... June 2, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that Dr. Pamela Pavco ... at the 23 rd World Congress ... will include in-depth presentations by world-class clinicians ...
(Date:6/2/2015)...  Alere Inc. (NYSE: ALR ), a ... House Antibiotic Stewardship Forum today to announce a ... the President,s National Action Plan to Combat Antibiotic-Resistant ... measurable goals and objectives over the next five ... protect their patients through antibiotic stewardship, slow the ...
(Date:6/2/2015)... Junction, AZ (PRWEB) June 02, 2015 ... light microscope technology, Yancy Corporation is enabling ... any desired material and biological sample, displaying the full ... electron bonds between atoms. , Jeff Porter, Co-Founder of ... physics are just that – rare. They come once ...
Breaking Biology Technology:Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2
... Madison, Wis. -- Rita Colwell, former director of ... Pollution and Human Health" at 5:30 p.m. Monday, Oct. ... of Wisconsin-Madison's Memorial Union. , ,Colwell headed the NSF ... Inc., and is a distinguished professor at the University ...
... Wis. -- Three Wisconsin businesses will receive funding ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , SonoPlot, Inc. is a Madison company established in ... $100,000 TVF loan to purchase equipment and develop a ...
... help of new silicon-based compounds, scientists - and patients ... the tiny lithium batteries used in implantable devices to ... lithium battery is the workhorse of implantable devices, which ... the central nervous system make critical connections in, for ...
Cached Biology Technology:New battery technology helps stimulate nerves 2New battery technology helps stimulate nerves 3
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... department operated by Georgia Tech and Emory University has ... to support a project aimed at reducing the incidence ... Manu Platt, an assistant professor in the Wallace H. ... Institutes of Health (NIH) funding to develop models for ...
... TEMPE, Ariz. Arizona State University has been awarded ... the National Institute of General Medical Sciences, part of the ... proteins that play a key role in protection against infectious ... ASU,s Department of Chemistry and Biochemistry in the College of ...
... provides evidence of the vicious cycle created when an ... food. Obese individuals have fewer pleasure receptors and ... of Texas at Austin senior research fellow and Oregon ... published this week in The Journal of Neuroscience ...
Cached Biology News:$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 2$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 3$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 4NIH funds center at Arizona State to battle infectious diseases 2NIH funds center at Arizona State to battle infectious diseases 3Research examines vicious cycle of overeating and obesity 2
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... Terminal deoxynucleotidyl transferase (TdT) is an intracellular ... cortical thymocytes and minor subpopulation of bone ... and increased numbers of TdT cells are ... leukaemias and lymphomas. Presence of TdT thus ...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: